FDA Approves First Therapy to Reduce Pancreatitis Risk - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves First Therapy to Reduce Pancreatitis Risk

In two placebo-controlled trials, triglyceride levels declined by up to 72% compared with placebo.

  • By

  • Kathryn Wighton

  • June 24, 2026

  • 2 min

Share

Objective:

To approve olezarsen (Tryngolza) for reducing triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.

Approach:
  • Clinical Trials: Two randomized, double-blind, placebo-controlled trials with 1,061 adults were conducted to evaluate the efficacy of olezarsen.
Key Findings:
  • Mean baseline triglyceride levels were 1,116 mg/dL.
  • In one trial, triglyceride levels decreased by 63% and 72% with 50-mg and 80-mg doses, respectively.
  • In the second trial, reductions were 49% and 55% with the 50-mg and 80-mg doses, respectively.
  • A pooled analysis indicated a lower incidence of acute pancreatitis in patients receiving olezarsen compared to placebo.
Interpretation:

The FDA recommends liver enzyme testing before treatment initiation and ongoing monitoring due to potential adverse reactions.

Limitations:
  • The trials primarily focused on short-term efficacy and safety.
  • Long-term effects and safety profile of olezarsen remain to be fully established.
Conclusion:

Olezarsen received Priority Review and Breakthrough Therapy designations for its indication.

Sources:

Original Source(s)

FDA Approves First Therapy to Reduce Pancreatitis Risk

  • by Kathryn Wighton

  • June 24, 2026

Related Content

How Does Social Media Influence Health Decisions?

National survey findings suggest many US adults report making health decisions based on social media despite widespread concerns about the accuracy of health information shared to the platforms.

Can Patients Switch to Biosimilar Aflibercept?

A 20-week INSIGHT extension suggests that switching from reference aflibercept to MYL-1701P maintained comparable safety, visual, and anatomic outcomes in patients with diabetic macular edema.

Upfront Cost Guidance Limited in US Guidelines

Although most large US-based medical societies in a cross-sectional study explicitly suggested considering economic or resource use–related evidence during guideline development, only 3.8% of individual recommendations included that information in the recommendation statement itself.